Efficacy and Safety Comparison of Add-on Therapy with Liraglutide, Saxagliptin and Vildagliptin, All in Combination with Current Conventional Oral Hypoglycemic Agents Therapy in Poorly Controlled Chinese Type 2 Diabetes
| Autor: | Xiao-Juan Liu, Qiu-Mei Zhang, Chun-Jun Li, Min Ding, Pei Yu, De-Min Yu, Qian Yu |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Blood Glucose Male China medicine.medical_specialty Pyrrolidines Endocrinology Diabetes and Metabolism Adamantane Type 2 diabetes Saxagliptin Pharmacology Hypoglycemia Gastroenterology chemistry.chemical_compound Endocrinology Asian People Glucagon-Like Peptide 1 Weight loss Diabetes mellitus Internal medicine Nitriles Internal Medicine Humans Hypoglycemic Agents Insulin Medicine Vildagliptin Glycemic business.industry Liraglutide Body Weight Dipeptides General Medicine Middle Aged medicine.disease Metformin Treatment Outcome Diabetes Mellitus Type 2 chemistry Drug Therapy Combination Female medicine.symptom business medicine.drug |
| Zdroj: | Experimental and Clinical Endocrinology & Diabetes. 122:469-476 |
| ISSN: | 1439-3646 0947-7349 |
| Popis: | To compare the efficacy and safety of adding liraglutide, saxagliptin and vildagliptin to current therapy in Chinese type 2 diabetes subjects with poor glycemic control.A 24-week, randomized, open-label, parallel clinical trial was performed. A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily). Glycosylated hemoglobin (HbA1c) values, fasting and postprandial blood glucose (FBG and P2BG), body weight, body mass index (BMI), episodes of hypoglycemia and adverse events were evaluated.Over the 24-week treatment period, greater lowering of mean of HbA1c was achieved with 1.2 mg liraglutide (-1.50%, 95% CI [-1.67, -1.34]) than with saxagliptin (-1.23%, 95% CI [-1.36, -1.11]) and vildagliptin (-1.25%, 95% CI [-1.37, -1.13]). There was no significant between-group difference of percentages of subjects who reached a target HbA1c |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|